Keyword: Arrowhead Research
Arrowhead Pharmaceuticals will assess ARO-HBV in combination with two undisclosed drugs selected by Johnson & Johnson.
The outlay, plus $1.6 billion in milestones, has bought J&J a drug that slashed levels of hepatitis B virus in a small, early-phase assessment.
The seroclearance gives a boost to Arrowhead as it plots a path back from safety concerns that derailed ARC-520 in 2016.
Caribou has seen biopharma vet and former Arrowhead exec Steven Kanner join the biotech.
A new upstart has launched today with the name of the planet from Frank Herbert's "Dune" as its moniker, denoting its desire to mine for potent new meds, although its focus is on a new kind of RNA target.
At the end of November, Arrowhead's hep B candidate, along with a host of others and 30% of its staff, were put under the ax as the biotech sought desperately to refocus.
Welcome to our new annual feature that aims to name and shame those biopharmas and medical device companies that made an attempt at being ripe but turned out to be rotten.
A few weeks back, and in fact the day before the U.S. election, RNAi biotech Arrowhead quietly posted some miserable news that its hep B candidate, ARC-520, was placed under a clinical hold by the FDA. Today, this candidate, along with a host of others and 30% of its staff, are to be axed as the biotech desperately seeks to refocus.
Late last night, seemingly in an effort to minimize exposure to the news as the U.S. election dominates, small cap Arrowhead Pharmaceuticals announced that the FDA has hit the biotech with a clinical hold for a small test of its hep B med ARC-520, which has previously been touted as a possible cure for the infection.
Arrowhead Pharmaceuticals and Spring Bank Pharmaceuticals have partnered to test a couple of hepatitis B candidates in combination.